Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038048 | 0.87 | EPHX2 (0.59) | KMT2ANPC1RAB9AMEN1IGF1R | |
| SCHEMBL18037970 | 0.86 | KMT2A (0.73) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL29556351 | 0.85 | P2RX1 (0.56) | KMT2AP2RX1MEN1IGF1REPHX2 | |
| SCHEMBL19900241 | 0.84 | KMT2A (0.70) | KMT2ANPC1RAB9AMEN1EPHX2 | |
| SCHEMBL30151329 | 0.84 | KMT2A (0.70) | KMT2ANPC1RAB9AMEN1EPHX2 | |
| SCHEMBL18038056 | 0.83 | KMT2A (0.72) | KMT2ANPC1RAB9AMEN1NTRK1 | |
| SCHEMBL19900334 | 0.82 | KMT2A (0.58) | KMT2ANPC1RAB9AIGF1REPHX2 | |
| SCHEMBL30151317 | 0.82 | KMT2A (0.58) | KMT2ANPC1RAB9AIGF1REPHX2 | |
| SCHEMBL19900302 | 0.82 | KMT2A (0.58) | KMT2ANPC1RAB9AMEN1IGF1R | |
| SCHEMBL23258580 | 0.81 | PIM1 (0.48) | KMT2ANPC1RAB9AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261631-B1 | INHIBITION OF OLIG2 ACTIVITY | CURTANA PHARMACEUTICALS INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20180244631-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2018-08-30 | — | — | US | disclosed |
| EP-3261631-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138479-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016138479-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885NPC1 4224/4885RAB9A 3638/4885 |
| US-20180244631-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885NPC1 4224/4885RAB9A 3638/4885 |
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KMT2A 501/4885NPC1 4224/4885RAB9A 3638/4885 |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885NPC1 4224/4885RAB9A 3638/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885NPC1 4224/4885RAB9A 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.